Ono Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 96 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Ono Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Ono Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Ono Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ono Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Ono Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Ono Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Ono Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate Ono Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Ono Pharmaceutical Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Ono Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Ono Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ono Pharmaceutical Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Ono Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Ono Pharmaceutical Co., Ltd. Snapshot 7
Ono Pharmaceutical Co., Ltd. Overview 7
Key Information 7
Key Facts 7
Ono Pharmaceutical Co., Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
Ono Pharmaceutical Co., Ltd. - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Combination Treatment Modalities 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Ono Pharmaceutical Co., Ltd. - Pipeline Products Glance 17
Ono Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 17
Phase III Products/Combination Treatment Modalities 17
Ono Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Ono Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
Ono Pharmaceutical Co., Ltd. - Drug Profiles 22
carfilzomib 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
nivolumab 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
remimazolam 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
anamorelin hydrochloride 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ivabradine 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ONO-2952 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ONO-4053 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ONO-6950 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ONO-9054 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
velcalcetide 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(levodopa prodrug + carbidopa) 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ONO-1266 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ONO-4059 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
NO-7268MX1 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ONO-7268MX2 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ONO-8055 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ONO-8539 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
opicapone 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
salirasib 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
E-0001163 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ONO-8430506 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
oprozomib 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecule to Block Kv1.3 for Central Nervous System, Immunology and Gastrointestinal Diseases 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecule to Inhibit Protease Enzyme for Undisclosed Indication 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules to Antagonize GPCR for Undisclosed Indication 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecules to Target Ion-Channels for Cardiovascular, Central Nervous System and Urological Diseases 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Ono Pharmaceutical Co., Ltd. - Pipeline Analysis 62
Ono Pharmaceutical Co., Ltd. - Pipeline Products by Target 62
Ono Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 64
Ono Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 65
Ono Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 66
Ono Pharmaceutical Co., Ltd. - Recent Pipeline Updates 68
Ono Pharmaceutical Co., Ltd. - Dormant Projects 88
Ono Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 89
Discontinued Pipeline Product Profiles 89
arundic acid 89
asimadoline 89
ceralifimod 90
freselestat 90
methylnaltrexone bromide 90
NIP-022 90
ONO-2506-PO 90
ONO-4127 90
ONO-5129 91
ONO-5334 91
ONO-6126 91
remimazolam 91
rivenprost 91
tecemotide 91
Ono Pharmaceutical Co., Ltd. - Company Statement 92
Ono Pharmaceutical Co., Ltd. - Locations And Subsidiaries 93
Head Office 93
Other Locations & Subsidiaries 93
Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 96
Disclaimer 96

List of Tables
Ono Pharmaceutical Co., Ltd., Key Information 7
Ono Pharmaceutical Co., Ltd., Key Facts 7
Ono Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014 9
Ono Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 12
Ono Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 13
Ono Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014 14
Ono Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014 15
Ono Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 16
Ono Pharmaceutical Co., Ltd. - Phase III, 2014 17
Ono Pharmaceutical Co., Ltd. - Phase II, 2014 18
Ono Pharmaceutical Co., Ltd. - Phase I, 2014 19
Ono Pharmaceutical Co., Ltd. - Preclinical, 2014 20
Ono Pharmaceutical Co., Ltd. - Discovery, 2014 21
Ono Pharmaceutical Co., Ltd. - Pipeline by Target, 2014 63
Ono Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014 64
Ono Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014 65
Ono Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 66
Ono Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014 68
Ono Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014 88
Ono Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2014 89
Ono Pharmaceutical Co., Ltd., Other Locations 93
Ono Pharmaceutical Co., Ltd., Subsidiaries 93